|Bid||1.5400 x 1100|
|Ask||1.5700 x 45900|
|Day's Range||1.5200 - 1.5800|
|52 Week Range||0.9500 - 6.9900|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
The Menlo Park, California-based company said it had a loss of 5 cents per share. The drugmaker posted revenue of $57,000 in the period. The company's shares closed at $1.82. A year ago, they were trading ...
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...
Geron Corporation (NASDAQ: GERN ) announced in September that Johnson & Johnson (NYSE: JNJ )'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, ...
April 8 (Reuters) - Geron Co Ltd: * SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 6 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2IiMtRX Further company coverage: ...
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2011 Chip Scarlett was appointed CEO Read More...
Geron Corporation (NASDAQ:GERN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is GERN will Read More...